FDA Brief

Warning letters Drugs

FDA warning letter to

DongBang Cosmetics Co., Ltd.

High riskIssued Oct 22, 2021Posted Nov 2, 2021Center for Drug Evaluation and Research | CDER

DongBang Cosmetics of Incheon shipped a hand sanitizer labeled 62% alcohol that tested at 55%, and it was refused at the U.S. border.

What happened

FDA tested a batch of MISSY KAY Premium Hand Sanitizer made at the firm's Incheon, South Korea facility when it was offered for import, and the shipment was detained and refused admission. The lab found an average of 55% ethanol by weight against the 62% stated on the label, which FDA says shows the firm's quality assurance (its own checks that each batch is made correctly) is not working. FDA also held a phone call with the firm on October 14, 2020 and says the firm repeatedly sent incomplete answers, including cosmetic quality documents instead of drug quality documents.

What FDA found

  1. The hand sanitizer had less alcohol than its label claimed, so its strength fell below what it said it had.

    Section 501(c) of the FD&C Act, 21 U.S.C. 351(c)
  2. The firm's quality system did not meet drug manufacturing quality rules, as shown by the low-strength batch and missing test records.

    Section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B); 21 CFR 211.84 and 211.165
  3. The product is a new drug sold without FDA approval and does not fit the over-the-counter rules that would let it be sold without approval.

    Sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a), 331(d); section 505G(a)(3)
  4. The label's alcohol strength claim is false and misleading because the product tested lower.

    Section 502(a) of the FD&C Act, 21 U.S.C. 352(a)
  5. The label has the product name in Korean as well as English, but the other required label information appears only in English.

    Section 502(c) of the FD&C Act, 21 U.S.C. 352(c); 21 CFR 201.15(c)(2)
  6. The label gives no complete U.S. address or phone number for consumers to report a serious adverse event.

    Section 502(x) of the FD&C Act, 21 U.S.C. 352(x)

What FDA wants

FDA tells the firm to answer in writing within 15 working days, including a full investigation of why the product tested at 55% instead of 62%, a list of raw material suppliers, a list of all batches shipped to the U.S., and complete batch records. FDA also strongly recommends hiring a qualified consultant to audit the whole operation before making drugs for the U.S. again.

Who should pay attention

  • U.S. importers and distributors of imported hand sanitizers and OTC antiseptics
  • brands that buy finished hand sanitizer from this contract manufacturer
  • cosmetics companies whose products carry drug-like claims such as antiseptic or disinfects

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Macau-Union Pharmaceutical Limited

    Macau-Union Pharmaceutical failed CGMP and sold unapproved, misbranded Bamboo Pharmacy OTC pain rubs in the U.S.

    High risk
  2. ImprimisRx NJ

    FDA found insanitary sterile compounding and subpotent timolol-latanoprost eye drops at ImprimisRx NJ.

    High risk
  3. Shuzy Rock Inc.

    FDA warns Shuzy Rock Inc. of adulterated hand sanitizers made under insanitary conditions and found below labeled alcohol strength.

    High risk
  4. Guangzhou Zhongkebaishi Health Industry Co., Ltd.

    Guangzhou Zhongkebaishi's Hand Sanitizer Gel, labeled 75% ethanol, tested at 51% and was refused US import.

    High risk